| 236.22 6.92 (3.02%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 298.02 | 1-year : | 339.42 |
| Resists | First : | 255.15 | Second : | 290.6 |
| Pivot price | 225.5 |
|||
| Supports | First : | 197.8 | Second : | 164.57 |
| MAs | MA(5) : | 232.26 |
MA(20) : | 232.35  |
| MA(100) : | 286.12 |
MA(250) : | 356.81 |
|
| MACD | MACD : | -10.5 |
Signal : | -14 |
| %K %D | K(14,3) : | 80.6 |
D(3) : | 66.4 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 495.54 | Low : | 197.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALNY ] has closed below upper band by 12.0%. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 239.14 - 240.28 | 240.28 - 241.34 |
| Low: | 225.49 - 226.77 | 226.77 - 227.97 |
| Close: | 234.09 - 236.13 | 236.13 - 238.05 |
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Fri, 21 Aug 2026
Enterprise value to revenue forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Fri, 21 Aug 2026
NewEdge Wealth LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Thu, 20 Aug 2026
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP - NewMediaWire
Thu, 20 Aug 2026
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Thu, 20 Aug 2026
Bragar Eagel & Squire, P.C. is Investigating Alnylam - GlobeNewswire
Thu, 20 Aug 2026
Securities Fraud Investigation Into Alnylam - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 134 (M) |
| Shares Float | 133 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 102.1 (%) |
| Shares Short | 5,770 (K) |
| Shares Short P.Month | 5,440 (K) |
| EPS | 5.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.11 |
| Profit Margin | 16.1 % |
| Operating Margin | 17.9 % |
| Return on Assets (ttm) | 12.3 % |
| Return on Equity (ttm) | 96.5 % |
| Qtrly Rev. Growth | 66.9 % |
| Gross Profit (p.s.) | 28.62 |
| Sales Per Share | 35.87 |
| EBITDA (p.s.) | 7.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 912 (M) |
| Levered Free Cash Flow | 272 (M) |
| PE Ratio | 41.15 |
| PEG Ratio | 0.4 |
| Price to Book value | 23.34 |
| Price to Sales | 6.58 |
| Price to Cash Flow | 34.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|